Please login to the form below

Not currently logged in
Email:
Password:

eye disorders

This page shows the latest eye disorders news and features for those working in and with pharma, biotech and healthcare.

Virtual reality

Virtual reality

Other groups are using VR applications to provide motor and cognitive training to stroke and multiple sclerosis patients, treat headache, correct eye disorders such as strabismus and help people cope with

Latest news

  • Bayer and Regeneron to develop second wet AMD therapy Bayer and Regeneron to develop second wet AMD therapy

    The partners already market Eylea (aflibercept) for use in a number of eye disorders, including wet AMD, and now want to develop a complementary therapy that can be used in combination ... The companies are banking on the two drugs complementing each

  • NICE backs two eye treatments NICE backs two eye treatments

    The National Institute for Heath and Care Excellence (NICE) today recommended two treatments for eye disorders for use on the NHS in England and Wales. ... Pathological myopia is a chronic form of myopia, which is characterised by excessive lengthening

  • ReNeuron wins orphan status for stem cell therapy ReNeuron wins orphan status for stem cell therapy

    ReN003 is being assessed as a treatment for rare eye disorder retinitis pigmentosa. ... of inherited eye disorders that affect the retina and can cause severe impairment to vision.

  • Lucentis cleared in Europe for pathological myopia Lucentis cleared in Europe for pathological myopia

    Pathological myopia affects 1 to 3 per cent of the world's population, in some patients leads to the growth of abnormal leaky blood vessels in the back of the eye ... in visual acuity after just two injections into the affected eye.

  • FDA approves Alcon eye drug Simbrinza FDA approves Alcon eye drug Simbrinza

    Fixed-combination licensed to treat glaucoma patients in the US. Novartis subsidiary Alcon has been given a boost after US regulators approved its fixed-combination eye treatment Simbrinza Suspension. ... This pressure is the only modifiable risk factor

More from news
Approximately 5 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics